Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$161.93 USD

161.93
3,100,660

+2.84 (1.79%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $161.85 -0.08 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

PacBio Enters Carrier Screening Market With PureTarget Expansion

by Zacks Equity Research

PACB expands its PureTarget portfolio, streamlining carrier screening with HiFi sequencing to meet rising global demand.

Zacks Equity Research

KMDA vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research

KMDA vs. ILMN: Which Stock Is the Better Value Option?

Sridatri Sarkar headshot

TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now?

by Sridatri Sarkar

As precision oncology advances, Tempus and Illumina lead the way with innovation. Which stock shows stronger growth momentum now?

Zacks Equity Research

Here's Why Illumina (ILMN) is a Strong Momentum Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Sridatri Sarkar headshot

Tempus AI Enhances Cancer Research Tools With FDA-Cleared xR IVD

by Sridatri Sarkar

TEM secures FDA clearance for its xR IVD device, advancing RNA-based cancer research and precision medicine tools.

Ekta Bagri headshot

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025

by Ekta Bagri

GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.

Zacks Equity Research

ILMN Stock to Gain From the Launch of Illumina Protein Prep Assay

by Zacks Equity Research

The Illumina Protein Prep rollout boosts multiomics, strengthens disease insights and supports ILMN stock momentum.

Zacks Equity Research

CRISPR Therapeutics (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

TMO Receives FDA Approval for Oncomine Dx Target Test

by Zacks Equity Research

Thermo Fisher secures FDA approval for its Oncomine Dx Target Test to identify NSCLC patients eligible for HERNEXEOS treatment.